ATE221125T1 - Klonierte glutaminsäure-decarboxylase - Google Patents

Klonierte glutaminsäure-decarboxylase

Info

Publication number
ATE221125T1
ATE221125T1 AT94927940T AT94927940T ATE221125T1 AT E221125 T1 ATE221125 T1 AT E221125T1 AT 94927940 T AT94927940 T AT 94927940T AT 94927940 T AT94927940 T AT 94927940T AT E221125 T1 ATE221125 T1 AT E221125T1
Authority
AT
Austria
Prior art keywords
cloned
acid decarboxylase
glutamine acid
glutamine
gad
Prior art date
Application number
AT94927940T
Other languages
English (en)
Inventor
Allan J Tobin
Mark G Erlander
Daniel L Kaufman
Michael J Clare-Salzler
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE221125T1 publication Critical patent/ATE221125T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51Lyases (4)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88Lyases (4.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y401/00Carbon-carbon lyases (4.1)
    • C12Y401/01Carboxy-lyases (4.1.1)
    • C12Y401/01015Glutamate decarboxylase (4.1.1.15)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/042Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/24Immunology or allergic disorders
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/975Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
AT94927940T 1993-09-17 1994-08-24 Klonierte glutaminsäure-decarboxylase ATE221125T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/123,859 US5674978A (en) 1990-09-21 1993-09-17 Peptides derived from glutamic acid decarboxylase
PCT/US1994/009478 WO1995007992A2 (en) 1993-09-17 1994-08-24 Cloned glutamic acid decarboxylase

Publications (1)

Publication Number Publication Date
ATE221125T1 true ATE221125T1 (de) 2002-08-15

Family

ID=22411325

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94927940T ATE221125T1 (de) 1993-09-17 1994-08-24 Klonierte glutaminsäure-decarboxylase

Country Status (11)

Country Link
US (5) US5674978A (de)
EP (1) EP0719340B1 (de)
JP (1) JP3133339B2 (de)
KR (1) KR100367943B1 (de)
AT (1) ATE221125T1 (de)
AU (1) AU697058B2 (de)
CA (1) CA2170523C (de)
DE (1) DE69431060T2 (de)
DK (1) DK0719340T3 (de)
ES (1) ES2179077T3 (de)
WO (1) WO1995007992A2 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2727377B2 (ja) 1990-09-07 1998-03-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 糖尿病自己抗体の検出方法
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
US6682906B1 (en) * 1990-09-21 2004-01-27 The Regents Of The University Of California Cloned glutamic acid decarboxylase
WO1992020811A2 (en) * 1991-05-15 1992-11-26 Zymogenetics, Inc. Cloning and expression of human islet glutamic acid decarboxylase autoantigen
DE69334246D1 (de) * 1992-12-03 2008-12-24 Univ California Verbesserte reagentien und methoden zur diagnose und behandlung von diabetes und stiff man syndrome
CN1112933A (zh) * 1994-01-20 1995-12-06 伯伦格·曼海姆有限公司 抗原特异性活化t淋巴细胞,其检测和用途
WO1996026218A1 (en) * 1995-02-20 1996-08-29 Amrad Operations Pty. Ltd. Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (iddm)
US5840307A (en) * 1995-03-31 1998-11-24 Immulogic Pharmacuetical Corp. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation
US5945401A (en) * 1995-06-23 1999-08-31 Conlon; Paul J. Peptide analogues of the 65KD isoform of human glutamic acid decarboxylase and uses thereof
DE19525784A1 (de) * 1995-07-14 1997-01-16 Boehringer Mannheim Gmbh Autoreaktive Peptide aus der humanen Glutamin-Decarboxylase (GAD)
DE19526561A1 (de) * 1995-07-20 1997-01-23 Boehringer Mannheim Gmbh In-vivo-Diabetes-Test
WO1997036618A1 (en) * 1996-04-01 1997-10-09 Chugai Seiyaku Kabushiki Kaisha Diagnostic composition for diseases accompanied by autoimmune reactions caused by 65k-glutamic acid decarboxylase
US7361331B2 (en) 1996-10-18 2008-04-22 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Plant bioreactors
US6815174B1 (en) * 1996-11-28 2004-11-09 Edgardo Poskus Thioredoxin-glutamate decarboxylase 65 fusion protein
FR2759701B1 (fr) * 1997-02-19 1999-06-04 Inst Nat Sante Rech Med Utilisation des proteines ulip dans le diagnostic et la therapie des cancers et des syndromes neurologiques paraneoplasiques
JP2001520200A (ja) * 1997-10-17 2001-10-30 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ウロキナーゼタイプのプラスミノーゲン活性化因子の内在化および分解を促進するための組成物および方法
SE9704451D0 (sv) * 1997-11-28 1997-11-28 Diamyd Therapeutics Ab New method and compositions for the treatment of autoimmune diseases
WO1999037315A1 (en) * 1998-01-27 1999-07-29 Bai Jane Pei Fan Chemical derivatives of autoantigens and autoimmune-suppressive peptides and pharmaceutical composition containing the same
US6303325B1 (en) 1998-05-29 2001-10-16 Dade Behring Inc. Method for detecting analytes
US6232082B1 (en) 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
EP1207895A4 (de) * 1999-08-23 2002-08-28 Virginia Mason Res Ct Peptide und ihre analoge zur behandlung und vorbeugung von diabetes
US6436401B1 (en) 1999-09-14 2002-08-20 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with diabetes and diabetic neuropathy comprising administration of low levels of antibodies
US6713058B2 (en) 1999-09-14 2004-03-30 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with neuropathic conditions comprising administration of low levels of antibodies
EP1149914B1 (de) * 2000-04-10 2008-06-18 Labor Dr. Merk und Kollegen GmbH Fusionsprotein zur gleichzeitigen Erkennung von humanen Autoantikörpern
EP1275003A2 (de) 2000-04-19 2003-01-15 Research Corporation Technologies, Inc Diagnostisches assay für endometriose
US7178152B2 (en) * 2001-03-01 2007-02-13 Sony Corporation Application programming interface for communication between audio/video file system and audio video controller
JP4594588B2 (ja) * 2001-04-10 2010-12-08 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ 抗体特異的プロファイルの治療的および診断的使用方法
AU2003300681A1 (en) * 2002-10-02 2004-05-04 Diamyd Medical Ab Formulation of glutarmic acid decarboxylase (gad65) and serum albumin
US20050250691A1 (en) * 2004-05-10 2005-11-10 Diamyd Therapeutics Ab Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
US20050209138A1 (en) * 2004-03-19 2005-09-22 Diamyd Therapeutics Ab Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
EP1755631A2 (de) * 2004-03-03 2007-02-28 Diamyd Medical AB Immunomodulation mittels therapeutischer verabreichung von medikamenten zur behandlung von diabetes und vorbeugung von autoimmuner diabetes
WO2006032126A1 (en) * 2004-09-24 2006-03-30 Syn X Pharma, Inc. Diagnosis and treatment of early pre-type-1 diabetes utilizing neuronal proteins
US7994279B2 (en) * 2006-04-04 2011-08-09 The University Of Toledo Altered peptide ligands of GAD65
CN100450552C (zh) * 2006-05-26 2009-01-14 中国医学科学院医学生物学研究所 Ⅰ型糖尿病疫苗及其构建方法
US20090098631A1 (en) * 2006-08-01 2009-04-16 Neurologix, Inc. Novel glutamic acid decarboxylase (GAD) proteins and methods of use
WO2008070222A2 (en) * 2006-08-21 2008-06-12 Cytotrend Biotech Engineering Limited Usa Inc A method of surface plasmon resonance (spr) technology to detect genomic disorders for prenatal diagnosis
US20100086920A1 (en) * 2006-09-18 2010-04-08 Cmed Technologies Ltd. Method to assess cancer susceptibility and differential diagnosis of metastases of unknown primary tumors
WO2008036470A2 (en) * 2006-09-19 2008-03-27 Cmed Technologies Ltd. A method for screening of infectious agents in blood
US20100047815A1 (en) * 2006-09-21 2010-02-25 Cmed Technologies Ltd. Method to detect tumor markers and diagnosis of undifferentiated tumors
US20100021971A1 (en) * 2006-09-21 2010-01-28 Cmed Technologies Ltd. Method to remove repetitive sequences from human dna
WO2008070227A2 (en) * 2006-09-25 2008-06-12 Cmed Technologies Ltd. A method for the identification of human immunodeficiency virus related antibodies in blood
US20100047789A1 (en) * 2006-09-25 2010-02-25 Cmed Technologies Ltd. Method of surface plasmon resonance (spr) to detect genomic disorders for postnatal diagnosis
US20100028856A1 (en) * 2006-09-25 2010-02-04 Cmed Technologies Ltd. Method to detect virus related immunological markers for the diagnosis of hepatitis b virus infection
US8119350B2 (en) * 2006-09-25 2012-02-21 Cmed Technologies Ltd Method of surface plasmon resonance (SPR) to detect genomic aberrations in patients with multiple myeloma
US20090311699A1 (en) * 2006-09-25 2009-12-17 Cmed Technologies Ltd. Method of surface plasmon resonance (spr) to detect genomic aberrations in patients with chronic lymphocytic leukemia
US20100041018A1 (en) * 2006-09-25 2010-02-18 Cmed Technologies Ltd. Method to detect virus related immunological markers for the diagnosis of hepatitis c virus infection
WO2008067003A2 (en) * 2006-09-27 2008-06-05 Cmed Technologies Ltd. A method to detect virus related immunological markers for the diagnosis of respiratory tract infections
WO2008066994A2 (en) * 2006-09-27 2008-06-05 Cmed Technologies Ltd. Application of surface plasmon resonance technology to maternal serum screening for congenital birth defects
US20100086937A1 (en) * 2006-09-27 2010-04-08 Cmed Technologies Ltd. method to detect treponema pallidum immunological markers for the diagnosis of syphilis
WO2008070241A2 (en) * 2006-09-27 2008-06-12 Cmed Technologies Ltd. A method to measure serum biomarkers for the diagnosis of liver fibrosis
WO2008066997A2 (en) * 2006-09-27 2008-06-05 Cmed Technologies Ltd. A method for quantitative measurement of cardiac biochemical markers
US8114682B2 (en) * 2006-09-27 2012-02-14 Cmed Technologies Ltd. Method for the quantitative evaluation of sex hormones in a serum sample
US8158440B2 (en) * 2006-09-28 2012-04-17 Cmed Technologies Ltd. Method for quantitative measurement of thyroid related antibodies or antigens in a serum sample
WO2008067006A2 (en) * 2006-09-28 2008-06-05 Cmed Technologies Ltd. A method for quantitative detection of diabetes related immunological markers
JP5378202B2 (ja) * 2007-03-15 2013-12-25 株式会社リバース・プロテオミクス研究所 脳・神経に特異的あるいは神経分化に特異的なバイオマーカー
JP5551448B2 (ja) 2007-03-16 2014-07-16 ジェノマティカ・インコーポレイテッド 1,4−ブタンジオールおよびその前駆体の生合成のための組成物および方法
MX2009011481A (es) * 2007-04-24 2010-02-01 Diamyd Therapeutics Ab Medicamentos y metodos para tratar enfermedad autoinmune y cancer.
US7947483B2 (en) 2007-08-10 2011-05-24 Genomatica, Inc. Methods and organisms for the growth-coupled production of 1,4-butanediol
WO2009045216A1 (en) 2007-10-04 2009-04-09 Cmed Technologies Ltd. Application of surface plasmon resonance technology for detecting and genotyping hpv
AU2009291825B2 (en) 2008-09-10 2016-05-05 Genomatica, Inc. Microorganisms for the production of 1,4-butanediol
JP5851243B2 (ja) 2008-11-30 2016-02-03 イミューサンティー インコーポレーテッドImmusanT,Inc. セリアック病の処置のための組成物および方法
ES2625623T3 (es) 2009-06-04 2017-07-20 Genomatica, Inc. Procedimiento de separación de componentes de un caldo de fermentación
EP4056706A1 (de) 2009-06-04 2022-09-14 Genomatica, Inc. Mikroorganismen zur herstellung von 1,4-butandiol und entsprechende verfahren
CN105441374A (zh) * 2009-10-13 2016-03-30 基因组股份公司 生产1,4-丁二醇、4-羟基丁醛、4-羟基丁酰-coa、腐胺和相关化合物的微生物及其相关方法
US8530210B2 (en) 2009-11-25 2013-09-10 Genomatica, Inc. Microorganisms and methods for the coproduction 1,4-butanediol and gamma-butyrolactone
US8445244B2 (en) 2010-02-23 2013-05-21 Genomatica, Inc. Methods for increasing product yields
US8048661B2 (en) 2010-02-23 2011-11-01 Genomatica, Inc. Microbial organisms comprising exogenous nucleic acids encoding reductive TCA pathway enzymes
US8852873B2 (en) 2012-04-13 2014-10-07 Diabetomics, Llc Maternal biomarkers for gestational diabetes
US11932845B2 (en) 2012-06-04 2024-03-19 Genomatica, Inc. Microorganisms and methods for production of 4-hydroxybutyrate, 1,4-butanediol and related compounds
EP3043812A1 (de) 2013-09-10 2016-07-20 Immusant Inc. Dosierung einer glutenpeptidzusammensetzung
SI3151853T1 (sl) * 2014-06-04 2020-10-30 Diamyd Medical Ab Dekarboksilaza glutaminske kisline (GAD) za uporabo v zdravljenju avtoimunske bolezni
AU2015323979A1 (en) 2014-09-29 2017-05-18 Immusant, Inc. Use of HLA genetic status to assess or select treatment of celiac disease
CA2968422A1 (en) 2014-11-21 2016-05-26 Immusant, Inc. Peptides for use in treatment and diagnosis of type 1 diabetes
GB202210967D0 (en) * 2022-07-27 2022-09-07 Univ Birmingham Tolerogenic peptides i

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624926A (en) * 1981-01-02 1986-11-25 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
US4487830A (en) * 1982-05-14 1984-12-11 American Hoechst Corporation Enzyme/immunofluorescent assay for autoantibodies
US4708871A (en) * 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4751181A (en) * 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
US5762937A (en) * 1988-12-13 1998-06-09 University Of Florida Research Foundation, Inc. Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
EP0448635B1 (de) * 1988-12-13 1995-09-20 University Of Florida Verfahren und zusammensetzungen zur früherkennung von behandlung der insulinabhängigen diabetes mellitus(iddm)
US5645998A (en) * 1988-12-13 1997-07-08 University Of Florida Research Foundation Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US6001360A (en) * 1988-12-13 1999-12-14 University Of Florida Method and compositions for early detection and treatment of insulin dependent diabetes mellitus
US5227159A (en) * 1989-01-31 1993-07-13 Miller Richard A Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies
NO306996B1 (no) * 1989-02-17 2000-01-24 Bayer Ag Isolert bukspyttkjerteloey-celle-(ICA)-antigen for in vitro- bruk
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
ES2093714T3 (es) * 1990-08-17 1997-01-01 Univ Florida Metodos y composiciones para la deteccion y el tratamiento precoces de la diabetes mellitus insulinodependiente.
US5512447A (en) * 1990-09-07 1996-04-30 The Regents Of The University Of California Methods for the diagnosis and treatment of diabetes
US5475086A (en) * 1990-09-21 1995-12-12 The Regents Of The University Of California Cloned glutamic acid decarboxylase peptides
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
AU8864791A (en) * 1990-10-02 1992-04-28 Trigen Incorporated Antibodies and methods for diagnosis and treatment of diabetes
DK0572478T3 (da) * 1991-02-22 2006-01-16 Inst Medical W & E Hall HBGAD- og HIGAD-polypeptider og nukleinsyre og anvendelse heraf til diagnostik og behandling af GAD-autoantigen-associerede sygdomme
WO1992020811A2 (en) * 1991-05-15 1992-11-26 Zymogenetics, Inc. Cloning and expression of human islet glutamic acid decarboxylase autoantigen
AU661684B2 (en) * 1991-06-18 1995-08-03 Regents Of The University Of California, The Cloned glutamic acid decarboxylase
US5200318A (en) * 1992-05-13 1993-04-06 Miles Inc. Diagnosis of IDDM with a panel of immunoreagents
US5837477A (en) * 1993-01-15 1998-11-17 The United States Of America As Represented By The Department Of Health And Human Services T cell receptor ligands and methods of using same
JP3908271B2 (ja) * 1993-03-05 2007-04-25 エピミューン,インコーポレイティド Hla−a2.1結合ペプチドおよびそれらの使用
US5547847A (en) * 1993-09-07 1996-08-20 University Of Washington Diagnosis of insulin-dependent diabetes

Also Published As

Publication number Publication date
EP0719340A1 (de) 1996-07-03
AU697058B2 (en) 1998-09-24
EP0719340B1 (de) 2002-07-24
US6011139A (en) 2000-01-04
US8926966B1 (en) 2015-01-06
ES2179077T3 (es) 2003-01-16
WO1995007992A2 (en) 1995-03-23
DE69431060T2 (de) 2002-11-14
US5846740A (en) 1998-12-08
CA2170523A1 (en) 1995-03-23
US6455267B1 (en) 2002-09-24
JPH09503387A (ja) 1997-04-08
KR100367943B1 (ko) 2003-06-18
WO1995007992A3 (en) 1995-06-22
US5674978A (en) 1997-10-07
CA2170523C (en) 2010-03-30
DE69431060D1 (de) 2002-08-29
KR960705051A (ko) 1996-10-09
JP3133339B2 (ja) 2001-02-05
DK0719340T3 (da) 2002-11-18
AU7920194A (en) 1995-04-03

Similar Documents

Publication Publication Date Title
ATE221125T1 (de) Klonierte glutaminsäure-decarboxylase
DK0708772T3 (da) Imidazo[4,5,-c]pyridin-4-aminer
AU1049788A (en) Methods and peptides for the treatment of non-ige-mediated diseases
DK0883687T3 (da) C-C CKR-5, CC-chemokinreceptor, derivater deraf og anvendelse deraf
HK102192A (en) Human tumor necrosis factor and dna therefor
ATE63748T1 (de) Enzymwiderstandsfaehige immunomodulatorische peptide.
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
WO1996019580A3 (en) Telomerase protein component
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
DE69334211D1 (de) Multidrug resistenz gen
RU94041224A (ru) Пептиды с органозащитной активностью, фармацевтическая композиция на их основе и их применение в терапии
HUT66309A (en) Bpc peptides, their preparation and therapeutic use
MY104909A (en) Peptide compounds.
DK1431391T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
GB9311454D0 (en) Pharmaceutical compositions
EP0293471A4 (de) Selbstantigen der primären lebercirrhose.
DE3569541D1 (en) Pharmacologically active peptides
FI961584A0 (fi) C-reaktiivisista proteiinifragmenteista johdetut oligopeptidit
ES8801316A1 (es) Un procedimiento para preparar un material peptidico que tiene actividad humoral timica
EP0317279A3 (de) Peptide für die Verwendung zur Reinigung von Faktor-VIII
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
ATE103979T1 (de) Menschliches lymphotoxin.
NO890932L (no) Modifiserte proteiner.
RU93013421A (ru) Штамм streptococcus faecium м-87, используемый в составе биоконсервантов, а также лечебно-профилактических препаратов

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification